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Emerging coronaviruses (CoV) are constant global public health threats to society.
Multiple ongoing clinical trials for vaccines and antivirals against CoVs showcase the
availability of medical interventions to both prevent and treat the future emergence
of highly pathogenic CoVs in human. However, given the diverse nature of CoVs
and our close interactions with wild, domestic and companion animals, the next
epidemic zoonotic CoV could resist the existing vaccines and antivirals developed,
which are primarily focused on Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS CoV). In late
2019, the novel CoV (SARS-CoV-2) emerged in Wuhan, China, causing global public
health concern. In this review, we will summarize the key advancements of current
vaccines and antivirals against SARS-CoV and MERS-CoV as well as discuss the
challenge and opportunity in the current SARS-CoV-2 crisis. At the end, we advocate
the development of a “plug-and-play” platform technologies that could allow quick
manufacturing and administration of broad-spectrum countermeasures in an outbreak
setting. We will discuss the potential of AAV-based gene therapy technology for
in vivo therapeutic antibody delivery to combat SARS-CoV-2 outbreak and the future
emergence of severe CoVs.
Keywords: coronavirus (CoV), vaccine, antivirals, adeno-associate virus, passive immunization strategy, MERS-
and SARS-CoV, 2019 nCoV
INTRODUCTION
The zoonotic transmission and subsequent adaptation to humans of emerging RNA viruses
is a global public health concern. In the 21st century alone, coronaviruses (CoV) have been
responsible for two separate endemics, the severe acute respiratory syndrome (SARS) and Middle
East Respiratory Syndrome (MERS) CoVs (de Wit et al., 2016). In late Dec 2019, a novel SARS-like
CoV designated 2019 nCoV emerged in Wuhan China, causing > 60,000 cases and over 1350 deaths
in an ongoing epidemic (Hui et al., 2020). Other highly pathogenic threat viruses that have emerged
in the 21st century include influenza viruses, Ebola viruses, flaviviruses and paramyxoviruses
(Mackenzie and Jeggo, 2013). The high mutation and recombination rate of RNA viruses
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drives the emergence of new viral strains that can rapidly adapt to
new and changing ecologies (Drake and Holland, 1999; Lauring
and Andino, 2010). Furthermore, industrialization, globalization
and traditional cultural habits potentiate the likelihood of
zoonotic transmission and facilitate the spread of viruses in
the human population. While new outbreaks from emergent
viruses are inevitable, scientists, epidemiologists, and the health
care industry are racing to develop new technologies to better
predict and minimize the impact of an outbreak by employing
global viral surveillance programs and developing vaccines and
antivirals (Lipkin and Firth, 2013). A major challenge of vaccine
and antiviral development is the elusive nature of the emerging
viruses, which oftentimes emerge from highly heterogeneous
populations of virus strains that circulate in animal reservoirs
(Lauring and Andino, 2010). Therefore, to prepare for future
outbreaks, vaccines and antivirals will need to be both potent
and broadly effective against multiple potential emerging viruses
within and across virus families. Additionally, in order to control
and prevent viral spread, treatments must be readily available
to affected populations and have a fast response time. In this
review, we will focus our discussion on the challenges, as well as
current development, of vaccines and antivirals for SARS-CoV
and MERS-CoV. At the end, we will also discuss the potential use
of AAV-based gene therapy as a quick response to prevent and
treat emerging viral infections in the current SARS-CoV-2 and
future outbreak situations.
Endemic and Emerging Coronaviruses
Coronaviruses are a diverse group of positive-stranded RNA
viruses which infect a wide range of animals from birds to
mammals, causing a variety of diseases (Perlman and Netland,
2009; Woo et al., 2009; Peck et al., 2015). Based on sequence
identity of the spike protein or the non-structural proteins
(nsp), CoVs are classified into four different sub-groups,
alphacoronaviruses, betacoronaviruses, gammacoronaviruses, and
deltacoronaviruses (Figure 1). Human coronaviruses (hCoVs),
such as 229E, OC43, NL-63 and HKU-1 are highly transmissible
respiratory viruses which are responsible for around 10-20%
of common cold cases annually (McIntosh et al., 1970; Cabeça
et al., 2013). HCoV-related illness is often self-limited in immune
competent individuals but may cause more severe upper and
lower respiratory tract infections in the young and elderly
population (Woo et al., 2005; Lau et al., 2006). In addition, highly
pathogenic CoVs may emerge through zoonotic reservoirs. In
the past two decades, SARS-CoV and MERS-CoV emerged
from bats and spread to humans through intermediate hosts
including civet cats and camels, respectively (Raj et al., 2014).
SARS-CoV and MERS-CoV belong to the sub-groups 2b and
2c of the Betacoronavirus genus (Peck et al., 2015). The latest
CoV outbreak is the SARS-CoV-2, a Betacoronavirus 2b which
emerged from bats and spread to humans (Lu et al., 2020).
The mortality rate of these viruses range from 10 to 40% but
can exceed 50% in the elderly (Min et al., 2004; Li et al., 2005;
Bolles et al., 2011b; Raj et al., 2014; Sharif-Yakan and Kanj, 2014;
World Health Organization [WHO], 2018). The unusually high
mortality rate is linked to disease progression leading to acute
respiratory distress syndrome (ARDS) which causes hypoxemia,
pulmonary edema, and infiltration of inflammatory immune cells
in the lung (Cabeça et al., 2013; Gralinski and Baric, 2015). If
unresolved, the diseases progress to late phase ARDS, leading to
end-stage lung disease and death (Ding et al., 2003). Currently,
no vaccines or antiviral drugs are approved to prevent or treat
severe CoV infection.
The Challenge for Vaccine Development
The CoV S-protein is the major envelope glycoprotein and
the main determinant of protective immunity. The S-protein
is composed of two principle subunits, S1 and S2; S1 governs
receptor binding and S2 is responsible for membrane fusion
(Li, 2016). Similar to other class I fusion proteins, S-protein
undergoes a major conformational change between pre-fusion
and post-fusion which also presents different antigenic epitopes.
While able to bind to both conformations, Abs targeting the
post-fusion form are not necessary neutralizing; in contrast,
Abs targeting the pre-fusion form of the S-protein correlate
better with neutralization. In particular, vaccines and neutralizing
antibodies (nAbs) which target the receptor binding domain
(RBD) of the S-protein can effectively neutralize the virus (Zhu
et al., 2007; Tang et al., 2014). However, due to high selective
pressure and tropism determinants, S-protein is the most diverse
region of CoV. For instance, the S-proteins from SARS-CoV and
MERS-CoV share only 44% sequence identity (Kandeel, 2018).
The majority of differences between S-proteins is in the S1 region,
which is further separated into the N-terminal Domain (NTD)
and RBD. The diverse nature of the RBD between SARS-CoV and
MERS-CoV is reflected in the use of different entry receptors,
either angiotensin I converting enzyme 2 (ACE2) or dipeptidyl
peptidase 4 (DPP4), respectively (Li et al., 2003; Raj et al., 2013).
The diversity of S-protein also renders vaccines and nAbs unlikely
to be cross-protective between existing and emerging CoVs.
Surveillance and experimental data have identified multiple
animal SARS- and MERS-like CoVs that have significant diversity
in S-protein and are able to replicate in human cells without
adaptation (Menachery et al., 2015, 2016; Luo et al., 2018).
Once transmitted to human population, such variation between
S-protein between the previous and the new emerging CoVs will
pose a major challenge on the progress of vaccine development.
CRITERIA FOR GENERATING EFFECTIVE
VACCINE FOR CoVs
Vaccine Criteria for SARS and
MERS-CoV Viruses
The surface glycoproteins are the main target for vaccine
development. In CoV infection, Abs against S-protein were
shown to be protective in multiple animal studies. Furthermore,
in a passive immunization study in camel, the nAb level is directly
correlated to lung pathology and survival (Zhao et al., 2015).
As such, one of the main goals for CoV vaccines in humans is
the ability to elicit a strong humoral immune response against
the S-protein. Particularly, the pre-fusion form of the S-protein
is an attractive target for Abs to confer protective immunity.
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FIGURE 1 | Spike and nsp12 phylogeny of representative coronaviruses. The Spike (A) and nsp12 (B) protein sequences of selected coronaviruses were aligned and
phylogenetically compared. Coronavirus genera are grouped by classic subgroup designations (1, 2a-d, 3, and 4). In the Spike tree in (A), SADS-CoV is designated
as 1* because of its distinctive grouping compared with more conserved proteins (e.g., nsp12, see (B)). Branches in each tree are labeled with consensus support
values (in %). Sequences were aligned using free end gaps with the Blosum62 cost matrix, and the tree was constructed using the neighbor-joining method based
on the multiple sequence alignment in Geneious Prime. Numbers following the underscores in each sequence correspond to the GenBank Accession number. The
SARS-CoV-2 is highlighted in red. The radial phylogram was exported from Geneious and then rendered for publication using Adobe Illustrator CC 2020.
In order to “lock” the S-protein in its antigenic optimal pre-fusion
form, two mutations, V1060P and L1061P, were introduced into
the MERS-CoV S-protein (Pallesen et al., 2017). The resulting
MERS S-2P is able to elicit both RBD and non-RBD binding
nAbs (Pallesen et al., 2017). The same strategy was also shown
to work in the SARS-CoV-2 S-protein (Wrapp et al., 2020).
Other structural proteins such as E and M and the nsp N also
contribute to viral protection and clearance (Channappanavar
et al., 2014; Zhao et al., 2016; Deng et al., 2018). Similarly to
other respiratory viruses such as influenza, mucosal IgA plays a
major role in disease protection and has a synergistic effect with
IgG (Belshe et al., 2000; Plotkin, 2010). In order to elicit a strong
mucosal IgA immunity, the route of vaccine administration
is important. Studies have shown that intranasal inoculation
of a recombinant RBD vaccine can elicit greater mucosal IgA
production than intramuscular or subcutaneous injection (Ma
et al., 2014a). However, the duration of mucosal antibodies
is typically shorter lived than systemic IgG responses and the
longest longitudinal study of MERS-CoV IgA responses ended
after 6 months (Hapfelmeier et al., 2010; Ma et al., 2014a). In
comparison, in a natural infection case study, SARS-targeting
systemic memory B cells were present up to 6 years for SARS-
CoV (Oh et al., 2012; Tang et al., 2019); and up to 34 months post
infection for MERS-CoV (Payne et al., 2016). Another important
consideration for SARS-CoV and MERS-CoV vaccination is the
T cell response against the virus, specifically the N proteins,
which is important for viral clearance (Zhao et al., 2010;
Channappanavar et al., 2014). A study has shown that adoptive
transfer of viral specific T-cells to SCID mice enhances survival
and reduces lung titer after SARS-CoV infection (Zhao et al.,
2010). Moreover, intranasal vaccination of N protein using the
VEEV replicon system elicits CD4+ memory T-cells responses
in the airway. Upon challenge, the airway CD4+ memory T cells
secrete IFN-γ, which subsequently enhances the innate immune
response as well as coordinates the CD8+ T cell priming and
migration which protects mice from lethal disease, but not weight
loss or virus titers under carefully controlled conditions (Zhao
et al., 2016). Interestingly, Rag−/− mice are able to clear SARS-
CoV infection, suggesting innate immunity is sufficient for viral
clearance (Zhao et al., 2010). However, the mechanism of this
viral clearance is still unknown. Another important aspect of
emerging CoV vaccine is the breadth of protection. As mentioned
previously, the antigenic variation in the S-protein between
CoVs limits the breadth of cross protection against multiple
emerging CoVs, and is especially true for S-protein only vaccines
(Wang et al., 2018, 2019).
Learning from natural infection, MERS-CoV specific CD4+
and CD8+ T cells are detected in PBMCs in MERS-CoV infected
survivors (Zhao et al., 2017). Therefore, a balance of B cell and T
cell responses is generally considered the gold standard to prevent
and resolve MERS-CoV and SARS-CoV infection. Multiple
strategies have been developed to elicit long lasting B and T
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cell responses for SARS-CoV and MERS-CoV. These include
the traditional live attenuated, inactivated, and subunit vaccines,
and newer development of nanoparticles, vectorized vaccines,
and RNA/DNA vaccines. In this review, we have selected only
the vaccine studies that have an in vivo challenge model and
have summarized the different parameters, including vaccine
components, dosage, challenge conditions, animal models and
the study outcome in Table 1. We will also discuss each type of
vaccine strategy and focus on the finished clinical trial targeting
SARS-CoV and the 3 ongoing clinical trials targeting MERS-
CoV using DNA (Martin et al., 2008; Modjarrad et al., 2019)
and vectorized vaccines. Other comprehensive reviews on CoV
vaccine development can be found elsewhere (Zhang et al., 2014;
Du and Jiang, 2015; Perlman and Vijay, 2016; Schindewolf and
Menachery, 2019; Yong et al., 2019).
Current Vaccine Strategies
Inactivated vaccines are the quickest option for vaccine
development in an outbreak situation. Multiple chemical and
physical methods have been applied singly or in combination
to inactivate CoVs, including β-propiolactone, formalin,
formaldehyde and UV. While multiple studies have shown the
efficacy of inactivated vaccines in hamster, ferret and multiple
mouse challenge models (Stadler et al., 2005; See et al., 2006,
2008; Spruth et al., 2006; Roberts et al., 2010), one study suggested
a potential vaccine enhanced pathologies (Bolles et al., 2011a).
In this study, double inactivation (DIV) of SARS-CoV using
formalin and UV+alum elicits a Th2 skewed response and is
only partially protective to young mice (6–8 weeks-old) and not
protective to experimentally aged mice (12–14 weeks-old) (Bolles
et al., 2011a). Furthermore, upon challenge, DIV vaccinated mice
show increased infiltration of eosinophils, neutrophils and other
inflammatory cell populations in the lung, likely due to the N
specific immune response (Bolles et al., 2011a). Further studies
have suggested that by replacing alum with TLR agonists such as
Poly I:C, Poly U or LPS as adjuvants, the skewed Th2 responses
can be alleviated and may reduce the infiltration of eosinophils
in the lung (Iwata-Yoshikawa et al., 2014).
Gamma-ray inactivated whole MERS-CoV (WIV) with alum
or M59 also suffers from the Th2 skewed immune response and
pulmonary eosinophilia upon challenge, suggesting a potential
risk of using inactive virus for CoV vaccination (Agrawal et al.,
2016). Interestingly, formaldehyde inactivated MERS-CoV co-
administered with alum and CpG shows a more balanced
Th1/Th2 response and is able to protect mice from a challenge
model (Ad5 transduced hDPP4) with reduction in lung viral titer
and improved lung pathology. There is no observable vaccine-
induced lung pathology or infiltration of eosinophils upon
challenge (Deng et al., 2018). The difference in vaccine outcomes
indicates an incomplete understanding of the effect of adjuvants
on the inactivated SARS and MERS-CoV vaccines. In respiratory
syncytial virus (RSV) vaccines, formalin inactivated vaccines
presents the post-fusion form predominately and fail to elicit
protective immune responses. Whether the same phenomenon
exists in inactivated CoV is still unknown, although it could
explain the discrepancy between reports. The inconsistent results
from different vaccine models also underscores the host genetic
elements affecting vaccine outcome. Nevertheless, inactivated
vaccine is still one of the most straightforward methods for
vaccine development and has the quickest response time in an
outbreak situation.
Live attenuated viral vaccines are the closest mimic of
natural infection and generally elicit strong B and T cell
responses (Zhao et al., 2017). Multiple strategies have been
used to genetically attenuate SARS-CoV and MERS-CoV by
either deleting or mutating structural, non-structural or accessory
proteins. Intranasal immunization of a SARS-CoV lacking E
protein (rSARS-CoV-1E) has shown complete protection from
pulmonary replication in a Golden Syrian hamster model
(Lamirande et al., 2008). A similar virus has been generated in
the MERS backbone, creating a conditional mutant that requires
trans expression of E for productive replication (Almazán
et al., 2013). Mutations of the DEDD motif of the 3′ to 5′
exonuclease (ExoN-nsp14) “proof-reading protein” on a mouse-
adapted SARS-CoV attenuated the virus both in vitro and in vivo.
A single intranasal immunization is able to elicit strong nAbs
(>6-fold protective titers) and completely protect against lethal
challenges in an aged mouse model (12 months-old BALB/c)
(Graham et al., 2012). Mutations in the nsp 16 (NSP16), a 2′O-
methyltransferase, in both SARS-CoV and MERS-CoV have also
been shown to attenuate the viruses and to protect BALB/c
and CRISPR-Cas humanized DPP4-288-330 mice from lethal
challenge (Menachery et al., 2014, 2017, 2018). Moreover, these
attenuation strategies can be multiplexed, leading to highly
stable live attenuated vaccines with limited capability to undergo
recombination and reversion repair (Graham et al., 2018;
Menachery et al., 2018). Although the live attenuated vaccine is
effective in small animal models, there remain safety concerns
about potential revertants and recombination with natural CoVs
which hinders their usage in the clinical setting. Furthermore, live
attenuated vaccines often require greater time for development
and safety testing which lessens utility in an outbreak situation.
Protein-based subunit vaccines are considered the safest
format of vaccine. However, the low immunogenicity of subunit
vaccines dictates a heavily reliance on adjuvants. Different forms
of the S-protein, including the S1 RBD, RBD-Fc (RBD with
human IgG Fc fusion), and N-terminal domain (NTD), have
demonstrated various degrees of nAb responses and protection in
multiple animal models including non-human primates (NHP)
(Lan et al., 2015; Zhang et al., 2016; Jiaming et al., 2017; Wang
et al., 2017; Deng et al., 2018; Nyon et al., 2018; Adney et al.,
2019). For instance, the SARS-CoV S1 subunit vaccine produced
from sf9 cells and with the adjuvant saponin or protollin are able
to reduce lung viral titer in young or aged mice after challenge,
respectively (Bisht et al., 2005; Hu et al., 2007). An RBD subunit of
SARS-CoV produced from Chinese hamster ovarian (CHO) cells
with Freund’s adjuvant is able to protect young BALB/c mice from
infection (Du et al., 2010). MERS-CoV-S1 with adjuvants MF59
or Advax HCXL is able to protect alpacas and dromedary camels
against MERS-CoV challenge (Adney et al., 2019). Adjuvant
selection can affect the vaccine outcome, and combinations of
adjuvants can have synergistic effects on the strength of the
response. For instance, rRBD with adjuvants alum and CpG ODN
together elicits a stronger humoral and cellular T cell response



















TABLE 1 | Summary of SARS-CoV and MERS-CoV vaccines studies
SARS-CoV
Vaccines
Antigens Vaccine formulations Dose, Time of vaccination Animal models Challenge dose. Virus





Inactivated SARS-CoV FRA (b-
propiolactone) + MF59
5 µg at 0, 2, and 4 weeks, SC BALB/c 104 TCID50 SARS-CoV Urbani,
IN
Protection, no virus detected in
Lung and Nasal Turbinates
Stadler et al., 2005 EID
Inactivated SARS-CoV Tor2 (b-
propiolactone) + Alum
50 µg at 0 and 4 weeks, SC 6 week old
129S6/SvEv
106 pfu SARS-CoV Tor2 at
week 3, IN
Protection See et al., 2006 JGV
Double Inactive SARS-CoV (Utah)
formaldehyde and UV
inactivation + Al(OH)3
0.08 – 0.2 µg at week 0 and 2,
SC
6 – 8 weeks CD1
mice
105 TCID50 SARS-CoV Utah
at week 3 or 11, IN
Protection, no virus detected in
lung and trachea
Spruth et al., 2006 Vaccines
Inactivated SARS-CoV Tor2 (b-
propiolactone) + Alum
50 µg at 0 and 4 weeks, SC 8 – 10 month old
ferret
106 pfu SARS-CoV Tor2 at
week 3, IN
Weak protection, slight
reduction of viral titer in lung,
BAL and nasal wash, slight
improvement in lung pathology




0.15 – 1.5 µg at week 0 and 3,
IM
BALB/c 105 TCID50 SARS-CoV Urbani
at week 3, IN
Protection, no virus detected in
lung
Roberts et al., 2010 Viral
Immunology
Inactivated SARS-CoV Urbina (b-
propiolactone) + AS01B
and AS03A
2.0 µg at week 0 and 3, IM 4 – 8 week old
Golden syrian
hamsters
103 TCID50 SARS-CoV Urbani
at week 4 or 18, IN
Partial protection, reduce viral
titer in lung
Roberts et al., 2010 Viral
Immunology
Double Inactive SARS-CoV MA15
formalin and UV
inactivated + Alum
0.2 µg at week 0 and
3–4 week, footpad
6 – 8 weeks old
BALB/cAnNHsd
105 PFU SARS-CoV MA15,
SZ61and GD03 at week 5, IN
Partial protection, reduce viral
titer in lung and good protection
from lethal challenge (MA15)
Bolles et al., 2011a JVI
Double Inactive SARS-CoV MA15
formalin and UV
inactivated + Alum
0.2 µg at week 0 and
3–4 week, footpad
12 – 14 months old
BALB/cAnNHsd
105 PFU SARS-CoV MA15,
SZ61and GD03 at week 5, IN
Weak protection, small drop in
viral titer in lung, weak
protection from leathal
challenge (MA15)
Bolles et al., 2011a JVI
LAV SARS-CoV-1E
(Urbani)
SARS-CoV-1E (Urbani) 103 TCID50 at 0 week, IN 7 week old Golden
syrian hamsters
103 TCID50 SARS-CoV Urbani
and GD03 at week 4, IN
Protection, no virus detected in
lung





102.5 or 104 PFU at week 12 months old
BALB/c
102.5 TCID50 SARS-CoV
MA15 at week 4, IN
Complete survival from lethal
challenge, no virus detected in
lung





102 PFU at week 0, IN 10 weeks old
BALB/c and
C57BL/6
105 PFU SARS-CoV MA15 at
week 4, IN
Complete survival from lethal
challenge, no viral titer
performed






102 PFU at week 0, IN 12 months old
BALB/c
105 PFU SARS-CoV MA15 at
week 4, IN
Complete survival from lethal
challenge, no virus detected in
lung
Menachery et al., 2018 JVI
Subunit subunit nS Sf9 SARS-CoV S (14-762)
Urbani + QS21
10 µg at week 0, 4, and 8, SC 6 weeks old
BALB/c
105 TCID50 SARS-CoV
(Urbani) at week 4, IN
Protection, reduce viral titer in
lung and nasal turbinates
Bisht et al., 2005 Virology
Ectodomain Sf9 SARS-CoV S
ectodomain
(Urbani) + Protollin
10 or 30 µg at week 0, 2 and
5, IN
∼ 1 year old
BALB/c
5x104 TCID50 SARS-CoV
Urbani at week 1, IN
Protection, reduce viral titer in
lung





































TABLE 1 | Continued
SARS-CoV
Vaccines
Antigens Vaccine formulations Dose, Time of vaccination Animal models Challenge dose. Virus
strains, Time after last
vaccination, Route
Results References
Subunit RBD219 CHO SARS-CoV RBD
(318-536)Tor2 + Freund
20 µg at week 0 and 10 µg at
week 3 and 6, SC
4 – 6 weeks old
BALB/c
5x105 TCID50 SARS-CoV
GZ50 at 10 day, IN
Protection, no virus
detected in lung
Du et al., 2010 viral
immunology
Subunit Trimer Spike trimer SARS-CoV RBD Spike Trimer
Urbani + Alum
50 µg at week 0, 3, and 6, SC 5 weeks old Golden
syrian hamsters
103 TCID50 SARS-CoV Urbani
at week 2, IN
Protection, no virus
detected in lung and
reduce pneumonitis
Kam et al., 2007 Vaccines
VLP MHV-S VLP SARS-CoV S in MHV + Alum 2 µg at 0 and 4 weeks 6 – 8 week old
BALB/c




Lokugamage et al., 2008
Vaccine
Flu M1-S SARS-CoV S Urbani in
influenza M1 + Al(OH)3
0.8 or 4 µg at week 0 and 3, IM6 – 8 weeks old
BALB/c
2xLD50 mouse adapted




virus detected in lung
Liu et al., 2011 Vaccines
DNA Plasmid S-Ectodomain Plasmid expressing SARS-CoV
S 1CD or ectodomain (Urbani)
25 µg at week 0, 3, and 6, IM 6 – 8 week old
BALB/c
104 TCID50 SARS-CoV Urbani,
at Day 30, IN
Protection, reduce viral
titer in lung and nasal
turbinates
Yang et al., 2004 Nature
Vector BHPIV3 SARS-S SARS-CoV S or SME Urbani in
parainfluenza virus type 3
vector (BHPIV3)
106 TCID50 at 0 week, IN Golden syrian
hamsters
103 TCID50 SARS-CoV Urbani
at week 4, IN
Protection, no virus
detected in lung
Buchholz et al., 2004 PNAS
BHPIV3 SARS-S SARS-CoV S Urbani in
parainfluenza virus type 3
vector (BHPIV3)








Bukreyev et al., 2004 Lancet
MVA-SARS-S SARS-CoV S Urbani in MVA 107 at 0 and 4 week, IN BALB/c 104 TCID50 SARS-CoV Urbani,
at week 8, IN
Protection, reduce viral
titer in lung and nasal
turbinates
Bisht et al., 2004 PNAS
MVA-SARS-S SARS-CoV S Urbani in MVA 107 at 0 and 4 week, IM BALB/c 104 TCID50 SARS-CoV Urbani,
at week 8, IN
Protection, reduce viral
titer in lung and nasal
turbinates
Bisht et al., 2004 PNAS
MVA-SARS-S SARS-CoV S and N Tor2 in
MVA
108 pfu at 0 and 5 × 107 at 2
week, IP and SC
Ferret 106 pfu SARS-CoV Tor2 at
week 4, IN
No protection
according to viral RNA
in lung, Ab induction
Czub et al., 2005 Vaccines
VSV-S VSV-SARS-S Urbani 1.4 × 104 pfu at week 0, IN BALB/c 104 TCID50 SARS-CoV Urbani
at month 1 and 4, IN
Protection, no virus
detected in lung and
nasal turbinates
Kapadia et al., 2005 Virology
hAd5 (N+S) Human Adenovirus 5 with
S + Ad5 N gene




106 pfu SARS-CoV Tor2 at
week 3, IN
No protection despite
strong IgG1, IgG2a Ab
induction and high
IFN-g secretion
See et al., 2006 JGV
hAd5 (N+S) Human Adenovirus 5 with
S + Ad5 N gene













































TABLE 1 | Continued
MERS-CoV
Vaccines
Antigens Vaccine formulations Dose, Time of vaccination Animal models Challenge dose. Virus
strains, Time after last
vaccination, Route
Results References
VEEV-S SARS-CoV GD03 S in VEEV 106 IU at 0 week, boost 3 –
5 weeks, footpad
4 – 7 weeks old 105 pfu SARS-CoV GD03 and
Urbani at week 7 – 8 and week
54, IN
Protection, no virus detected in
lung
Deming et al., 2006
PlOS Med
VEEV-S SARS-CoV GD03 S in VEEV 106 IU at 0 week, boost 3 - 5
week, footpad
> 26 week old 105 pfu SARS-CoV GD03 and
Urbani at week 7 -8 and week
54, IN
No protection Deming et al., 2006
PlOS Med
hAd5-S + AdC7-S Human Adenovirus 5 with
S + Chimpanzee AdC7 with S
Tor2
5 × 1011 VP/kg at 0 and 1
month, IM
18 – 20 weeks old ferret 106 pfu SARS-CoV Tor2 at
not specify, IN
Protection, reduce viral titer in
lung and nasal turbinates
Kobinger et al.,
2007 Vaccines
hAd5 (N+S) Human Adenovirus 5 with
S + Ad5 N gene
1 × 109 pfu each at 0 and
4 weeks, IM




See et al., 2008
JGV
hAd5 (N+S) Human Adenovirus 5 with
S + Ad5 N gene
1 × 109 pfu each at 0 and
4 weeks, IN








Inactivated MERS-CoV (γ-ray) + Alum or
MF59





MERS-CoV at week 3, IN
Protection from virus
replication, no virus detected in
lung, increase lung pathology




(formaldehyde) + Alum and
CpG
1 µg at week 0, 4 and 8, IM 14 – 16 week old BALB/c
transduced with hDPP4 by
Ad5
105 PFU MERS-CoV
(EMC/2012) at week 2, IN
Protection, no virus detected in
lung








106 PFU at week 0, IN 10 - 20 week old C57BL/6
288-330+/+
106 PFU MERS-CoV EMC MA1
at week 4, IN
Complete survival from lethal




Subunit RBD MERS-CoV RBD S367-606
(EMC/2012) + alum
200 µg at week 0 and 100 µg
at week 8 and 25, IM
Rhesus Macaque 6.5x107 TCID50 MERS-CoV
(EMC/2012) at week 2, IN
Partial protection, reduce viral
titer in lung and trachea
Lan et al., 2015
EBioMedicine
NTD MERS-CoV NTD S18-353
(EMC/2012) + alum and CpG
5 or 1 µg at week 0, 4 and 8,
IM
16 – 18 weeks old BALB/c
transduced with hDPP4 by
Ad5
105 PFU MERS-CoV
(EMC/2012) at week 2, IN
Partial protection, reduce lung
and trachea pathologies, no
viral titer information
Jiaming et al., 2017
Vaccines
S ectodomain MERS-CoV EMC/2012 S
ectodomain + Alum and CpG
1 µg at week 0, 4 and 8, IM 14 – 16 week old BALB/c
transduced with hDPP4 by
Ad5
105 PFU MERS-CoV
(EMC/2012) at week 2, IN
Protection, reduction in lung
viral titer
Deng et al., 2018
Emerging Microbes
and infection
RBD-Fc MERS-CoV RBD S377-588 Fc
(EMC/2012) + MF59
10 µg at week 0, 3, and 6, SC 4 – 6 weeks old BALB/c
transduced with hDPP4 by
Ad5
105 PFU MERS-CoV
(EMC/2012) at week 2, IN
Protection, no virus detected in
lung




RBD-Fc MERS-CoV RBD S377-588 Fc
(EMC/2012) + Addavax





Complete survival from lethal
challenge, no virus detected in
lung






































TABLE 1 | Continued
MERS-CoV
Vaccines
Antigens Vaccine formulations Dose, Time of vaccination Animal models Challenge dose. Virus
strains, Time after last
vaccination, Route
Results References
S1 MERS-CoV ENgland1 S1 +
Advax HCXL or Sigma
oil-in-water emulsion
400 µg at week 0, 4 and 15, IM dromedary camel 107 TCID50 MERS-CoV
(EMC/2012) at ∼week 4, IN
Protection, reduce viral
titer in lung and nasal
turbinate
Adney et al., 2019
Virus
S1 MERS-CoV ENgland1
S1 + Advax HCXL or Sigma
oil-in-water emulsion
400 µg at week 0, 4, and 15,
IM
Alpaca 107 TCID50 MERS-CoV
(EMC/2012) at ∼week 4, IN
Protection, no virus
detected in lung, nasal
turbinate and nasal
swabs
Adney et al., 2019
Virus
Subunit Trimer RBD Trimer MERS-CoV RBD-Fd
(Trimer) + alum
5 µg at week 0 and 4, IM hCD26/DPP4
transgenic mice
104 TCID50 MERS-CoV
(EMC/2012) at week 12, IN
Complete survival from
lethal challenge, no viral
titer performed
Tai et al., 2016
Virology
VLP S nanoparticles MERS-CoV Jordan S
nanoparticle + Matrix M1
10 µg at week 0 and 3, IM 15 – 17 weeks old
BALB/c transduced
with hDPP4 by Ad5
2.5 × 103 PFU MERS-CoV






BNSP333-S MERS-CoV S1 Jordan
fused with rabies virus G
protein VLP
10 µg at week 0, 1, and 3, IM 15 – 17 weeks old
BALB/c transduced
with hDPP4 by Ad5
2.5 × 103 PFU MERS-CoV
(Jordan) at week 4, IN
Protection, no virus
detected in lung
Wirblich et al., 2017
JVI
DNA Plasmid S-protein Plasmid expressing
MERS-CoV S1
(Al-Hasa_1_2013)
0.5 or 2 mg at week 0, 3 and 6,
IM
Rhesus macaques 7 × 106 TCID50 MERS-CoV
(EMC/2012) at week 5, IT, IN,
oral and ocular
Protection, reduce viral




Plasmid S1 Plasmid expressing
MERS-CoV S1
(Al-Hasa_15_2013)
100 µg at week 0, 3 and 6, IM 14 - 16 week old
BALB/c transduced
with hDPP4 by Ad5
105 PFU MERS-CoV
(EMC/2012) at Day 18, IN
Protection, reduce viral
titer in lung
Chi et al., 2017
Vaccines




(EMC/2012) S or soluble S





7 × 104 TCID50 MERS-CoV
(EMC/2012) at week 6, IN
Protection, reduce viral




ChAdOx1 MERS ChAdOx1 with MERS-CoV
S-protein (EMC/2012)
108 IU at week 0, IN or IM hCD26/DPP4
transgenic mice
104 TCID50 MERS-CoV
(EMC/2012) at week 4, IN
Complete survival from
lethal challenge, no




MVA-MERS-S MVA with MERS-CoV
S-protein
106, 107, or 108 PFU at week
0, IM or SC
14 – 16 week old
BALB/c transduced
with hDPP4 by Ad5
7 × 104 TCID50 MERS-CoV
(EMC/2012) at week 6, IN
Protection, reduce viral
RNA genome in lung,
reduce lung pathology
Volz et al., 2015 JVI
rAd5-S1/F/CD40L hAd5 with MERS-CoV S1
trimer fused with CD40L
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(Lan et al., 2014). Additionally, rNTD with alum is able to reduce
lung pathology in a non-lethal MERS-CoV challenge (Jiaming
et al., 2017). Instead of adjuvants alone, immune enhancers such
as an Fc fragment, which increases the protein half-life when
fused with the RBD, can also elicit a stronger IgG nAb and
cellular immune response in multiple experimental animals (Du
et al., 2013; Ma et al., 2014b; Tang et al., 2015; Nyon et al.,
2018). RBD-Fc fusion subunit vaccine is able to protect a lethal
challenge of MERS-CoV in adenovirus transduced hCD26/DPP4
mice (Zhang et al., 2016; Wang et al., 2017). While a large amount
of work concerning the subunit vaccines has been done in
conjunction with different adjuvants, the effect of each adjuvant is
not well understood and multi-adjuvant systems (combinatorial
admixes) have not been rigorously tested. A more systematic
method of studying the effect of different adjuvants on CoV
vaccines will be valuable for vaccine development, perhaps using
genetic reference populations that more accurately phenocopy
human genetic variation (Leist and Baric, 2018).
Trimeric forms of the S-protein and RBD have been
developed using the T4 trimerization domain to mimic the
native conformation of the spike RBD (Kam et al., 2007; Tai
et al., 2016). The trimeric RBD antigens are able to elicit a
robust nAb response and protect 80% of hDPP4 transgenic mice
from lethal MERS-CoV challenge, although most animals still
experienced slight weight loss (Tai et al., 2016). Alternatively, the
MERS-CoV S-protein has been structurally designed to remain
in perfusion state by mutating V1060 and L1061 at the tip of
the central helix to proline (S-2P) (Kirchdoerfer et al., 2016;
Pallesen et al., 2017). The MERS S-2P protein retains the receptor
binding properties of the wild-type S and elicits nAbs against
at least 3 different S domains, including RBD, NTD, and S2.
Intramuscular injection of the MERS S-2P elicits nAb responses
in mice comparable to the monomeric S1 and trimeric S-protein
antigens. (Pallesen et al., 2017).
Similar to subunit vaccines are the viral like particle (VLP)
and nanoparticle vaccines. VLP and nanoparticles provide
multivalent binding similar to actual viruses without the potential
safety concerns. In SARS-CoV, multiple systems were used to
generate S-protein VLPs, including the mouse hepatitis virus
(MHV) and influenza matrix 1 (M1). In the chimeric MHV
system, the SARS-CoV protein is co-expressed with the MHV
E, M and N proteins to produce MHV-S VLP. Mice vaccinated
with the MHV-S VLP and alum have inhibited viral replication
in lung after a homologous strain challenge (Lokugamage et al.,
2008). Instead of using MHV structural proteins, the influenza
system express the SARS-CoV S-protein with influenza virus M1
proteins in Sf9 cells to create the M1-S VLP. Immunization of
M1-S VLP with aluminum hydroxide can protect mice from
a lethal challenge of SARS-CoV (Liu et al., 2011). In MERS-
CoV, expression of S, E, and M proteins using the baculovirus
system produces VLPs that are morphologically similar to the
actual virus (Coleman et al., 2014; Wang et al., 2017b). Other
methods such as CPV-based (Wang et al., 2017a), rabies virus
(MV)-based (Wirblich et al., 2017), ferritin-based (Seong, 2018),
and S-protein aggregates (Coleman et al., 2014) are all able
to elicit immune responses and reduce viral replication in a
mouse model when co-administered with Matrix M1 adjuvant
(Coleman et al., 2017). Although all show different degree of
immune response in animal, only one study showed a reduction
of viral titer in vivo via an adenovirus transduced hCD26/DPP4
mouse model (Coleman et al., 2017).
Clinical Trials for SARS- and MERS-CoV
Vaccines
A finished phase 1 clinical trial for a SARS-CoV vaccine is a DNA
vaccine that encodes the ectodomain of the SARS-CoV S-protein
(NCT00099463). DNA vaccines rely on a continuous expression
of antigen from a DNA plasmid that is injected intramuscularly
and electroporated (Muthumani et al., 2015; Wang et al.,
2015; Chi et al., 2017). In pre-clinical studies, 3 doses of an
intramuscular plasmid injection was able to reduce viral titer in
both lung and nasal turbinate in a BALB/c challenge model (Yang
et al., 2004). The phase 1 trial showed favorable results; after 3
doses of DNA vaccine, all subjects showed CD4+ T cell responses,
while 80% of subjects had nAbs and 20% of subjects showed
CD8+ T cell responses. However, there has been no follow-up
in the vaccine development, likely due to the end of the SARS-
CoV outbreak (Martin et al., 2008). One MERS-CoV vaccine
that is currently undergoing clinical trials (NCT03721718) is
a DNA-based vaccine (Modjarrad et al., 2019). GLS-5300 is a
DNA vaccine based on a consensus full-length S-protein from
MERS-CoV under the control of a CMV promoter. In preclinical
studies, the vaccine was electroporated into mice, camel and
rhesus monkeys three times within 1 month. The vaccine elicited
B cell responses in all animals at 1 month post vaccination,
and extracted IgG was able to neutralize multiple strains of
MERS-CoV including England/2/2013, and Al-Hasa/1/2013 and,
surprisingly, a group 1b CoV NL63 and a group 2a CoV HKU1
using the pseudotype neutralization assay (Muthumani et al.,
2015). T cell responses were assessed in mice and monkeys, with
both demonstrating T cell responses as indicated by the presence
of IFN-γ, TNFα and IL2-secreting CD4+ and CD8+ T cells
after peptide stimulation. Rhesus monkeys were also protected
from challenge of the vaccine strain with lower viral titers and
lung pathology as assessed by radiography and pathology studies
(Muthumani et al., 2015). Currently, GLS-5300 has completed
Phase I clinical trials (safety). Three doses (0.67, 2, and 6 mg)
of GLS-5300 were electroporated intramuscularly at weeks 0,
4, and 12. Ninety-four percent of subjects were seroconverted
and nAbs were detected in 50% of the individuals. Seventy-six
percent of subjects developed T-cell responses against peptides
derived from MERS-CoV S-proteins (Modjarrad et al., 2019).
Other than a full S-protein DNA vaccine, different designs also
show promising results in preclinical mouse models. Notably, a
DNA vaccine composed of only the S1 domain showed efficacy
when paired with different adjuvants (Chi et al., 2017). Hybrid
strategies using a DNA vaccine paired with a protein booster also
showed promising results in eliciting more balanced Th1 and Th2
responses (Wang et al., 2015; Al-Amri et al., 2017).
Vector-Based Vaccines
Two out of the three clinical trials for MERS vaccines are
vectorized vaccines. Viral vector-based vaccines have multiple
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advantages over the generic protein or DNA-based subunit
vaccines. Firstly, as viral vectors utilize a defined viral entry
mechanism, they are more efficient at delivering DNA into cells.
Second, the vector itself can serve as an adjuvant which in turn
elicits both B- and T-cell responses (Ura et al., 2014). Finally, a
wide variety of vector systems including measles viruses (Malczyk
et al., 2015; Bodmer et al., 2018), Venezuelan equine encephalitis
virus (VEEV) replicon system (Deming et al., 2006; Agnihothram
et al., 2014; Zhao et al., 2016), adeno-associated virus (AAV) (Du
et al., 2008), parainfluenza type 3 (BHPIV3) (Buchholz et al.,
2004; Bukreyev et al., 2004), human and chimpanzee adenovirus
(hAd5 and ChAdOx1) (See et al., 2006, 2008; Kobinger et al.,
2007; Kim et al., 2014; Guo et al., 2015; Hashem et al., 2019) and
modified vaccinia virus Ankara (MVA) (Bisht et al., 2004; Czub
et al., 2005; Kapadia et al., 2005; Haagmans et al., 2016) have been
previously established for use as vaccine platforms for multiple
infectious diseases. Herein, we will focus on the three systems
that have been or are currently under clinical trial; all others are
summarized in Table 1.
Replication-defective adenovirus vectors are one of the most
effective choices to deliver vaccine antigens. Human adenovirus
5 (hAd5) and enteric adenovirus type 41 (Ad41) have both
been used to deliver MERS-CoV S or S1 proteins. Intramuscular
inoculation of the vaccine elicits both B-cell (nAb titer) and
T-cell (IFN-γ secreting splenocytes and pulmonary lymphocytes)
responses (Guo et al., 2015). However, pre-existing nAbs against
hAd5 and 41 in the human population have limited their
usage to dromedary camels instead of humans (Chirmule et al.,
1999). The pre-existing nAb problem against hAd5 can be
circumvented by using a chimpanzee adenovirus. One such
platform is ChAdOx1, wherein the adenovirus E1 gene is replaced
by a MERS-CoV S-protein with an N-terminal secretion peptide
from human plasminogen activator (tPA) driven by a CMV
promoter. Intramuscular inoculation of the vector successfully
elicits nAbs against S-protein as quickly as 14 days post infection.
Splenic CD8+ T-cells secreting IFN-γ, TNF-α and IL-17 are also
present at 28 days post infection (Alharbi et al., 2017). A single
intranasal or intramuscular inoculation of ChAdOx1-MERS is
able to protect a human DPP4 transgenic mouse from lethal
challenge by MERS-CoV, and the vaccine (Munster et al., 2017) is
currently under phase 1 clinical trial (NCT03399578). CHAdOx1
has also shown effective protection for Rift Valley Fever Virus in
dromedary camels (Warimwe et al., 2016).
The modified vaccinia virus Ankara (MVA) vector is
another effective platform for MERS-CoV vaccine development.
S-protein is inserted into the MAV genome at deletion site III
driven by the viral P11 promoter. After a single intramuscular
injection, BALB/c mice produce nAbs against both the RBD
and S2, as tested in vitro (Song et al., 2013). A follow-up
study identified IFN-γ secreting splenocytes after peptide S291
stimulation at 56 days post infection, suggesting the vaccine is
able to elicit memory CD8+ T cell responses. The vaccine is also
able to protect a hDDP4-transduced BALB/c mouse model. RNA
genomes in the lungs and lung pathology are drastically reduced
compared to mock vaccination (Volz et al., 2015). The MAV
based MERS-CoV vaccine has also been tested on dromedary
camels and elicits induction of nAbs in sera and nasal swabs.
Vaccinated camels also show reduced RNA genomes and gross
pathology. The Phase I clinical trial has just been completed and
the results are pending (NCT03615911).
ANTIVIRALS
The Challenge for Treatment Windows
The average incubation period for SARS-CoV and MERS-CoV
is around 5 days (Zumla et al., 2015; de Wit et al., 2016)
and the main site of viral replication is the lower respiratory
tract (Corman et al., 2015; Petrovsky, 2016). At 7–10 days after
symptomatic onset, viral RNA titer peaks in the upper respiratory
tract (Drosten et al., 2004; Corman et al., 2015). For terminal
cases, disease lasts for an average of 12 days post symptomatic
onset for MERS-CoV and 24 days for SARS-CoV (Zumla et al.,
2015). Interestingly, severe symptoms begin as the viral titer is
decreasing, suggesting that severe CoV pathogenesis is due to
immune complications and the inability to resolve inflammation
(Peiris et al., 2003a; Wang et al., 2004). SARS-CoV upregulates
pro-inflammatory cytokine production in the lung, including
IL1, IL6, IL8, IL10, CXCL10 and TNF-α production (Binnie
et al., 2014). Compared to SARS-CoV infected patients with
mild diseases, patients with ARDS fail to induce interferon (IFN)
expression and the subsequent IFN-stimulated genes (ISGs) that
are indicative of adaptive immune responses (Cameron et al.,
2007; Binnie et al., 2014). The inability to switch from an innate
immune response to the adaptive immune response may lead to
uncontrollable inflammation and severe end stage lung disease.
Given the rapid progression of symptoms to terminal illness,
there is only approximately a 1 week treatment window after
the onset of symptoms for antiviral and medical intervention
(Widagdo et al., 2017). This treatment window could further
compromised by delays in virus diagnosis, causing a challenge
for timely medical intervention administration when the virus
titers and pathological symptom are relatively mild (Corman
et al., 2015; Ahmed, 2019). Unlike humans, experimental animal
models have a compressed disease course (<7 days), and it is
difficult to differentiate between early and late phase of infection.
It would be beneficial for clinical studies to separate the early-
(<10 days) and late-phase (>10 days) patients to determine
differences in patient response between the groups.
The Challenge for Therapeutic
Development
Despite of the presence of a 3′ to 5′ exoribonuclease (exoN)
proofreading enzyme, their large genome size (28–30 kb)
means that CoVs remain in the category of highly mutating
viruses (Eckerle et al., 2007, 2010; Denison et al., 2011). The
high mutation rate poses a considerable challenge for antiviral
development as drug resistant viruses could arise or already
exist within the quasispecies in nature or from an infected
individual (Briese et al., 2014). For instance, after a prolonged
period of nAb or drug treatments, the CoV can acquire mutations
which confer resistance to the therapeutics (Zumla et al., 2016a).
The appearance of these “escape viruses” has been confirmed
in multiple mouse model studies in well-contained laboratory
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FIGURE 2 | Schematic of the CoV replication cycle and key steps for antiviral targets. White text boxes indicate the subtype of antivirals that work either
extracellularly or intracellularly. Different steps of the CoV replication cycle are illustrated in cartoon form, including receptor binding, membrane fusion, viral RNA
replication, sub-genomic RNA transcription and translation.
settings as well as in nature (Neuman et al., 2006; Ter Meulen
et al., 2006; Huang et al., 2008; Jiang et al., 2014; Tang et al., 2014;
Tai et al., 2017; Kleine-Weber et al., 2019). Fortunately, some of
the mutations that confer drug resistance also compromise viral
fitness and attenuate the virus (Deng et al., 2014; Agostini et al.,
2018). Another therapeutic intervention is the use of immune
modulators, such as IFN-α2a/2b, IFN-β1b and corticosteroids in
treating CoVs (Loutfy et al., 2003; Peiris et al., 2003b; Sung et al.,
2004). Although multiple studies have shown efficacy of IFN-
α2a/2b and IFN-β1b singly or in combination with off-labeled
antivirals such as ribavirin, lopinavir (LPV) and ritonavir (RTV)
in treating SARS- and MERS-CoV in mouse, rhesus monkey and
marmoset models (Haagmans et al., 2004; Barnard et al., 2006b;
Falzarano et al., 2013b; Chan et al., 2015), clinical studies have
shown inconclusive results (Momattin et al., 2013; Mo and Fisher,
2016). Currently, a randomized controlled trial is underway to
determine the efficacy of a combination of LPV/RTV and IFN-
β1b in treating MERS-CoV infection (NCT02845843).
Convalescent Plasma and Monoclonal
Antibodies
Although there is no approved drug to treat severe CoV
infection, multiple strategies have shown promising results in
an experimental setting (Figure 2). Convalescent plasma (CP)
is derived from patients who have recovered from SARS-CoV
and MERS-CoV infection and contains high titer nAbs (Hsueh
et al., 2004; Al Kahlout et al., 2019; Shin et al., 2019). Some data
suggest that CP use against SARS-CoV infection is safe and, when
administered at an early time point, may reduce mortality (Mair-
Jenkins et al., 2015). CP neutralizing titers > 1:80 may have a
positive impact on infected MERS-CoV patients with respiratory
failure (Ko et al., 2018). Unfortunately, CP from convalescent
patients is difficult to obtain in large quantities and the Ab titer is
too low to have beneficial effects, making it difficult to be used as a
main stream therapeutic or for clinical testing (Arabi et al., 2016).
As such, no systematic, well-designed clinical trial has formally
demonstrated the efficacy of CP in emerging CoV infection.
Rather, a clinical trial for testing CP against MERS-CoV infection
was withdrawn prior to patient enrollment (NCT02190799).
Although CP from convalescent patients is difficult to obtain,
the active component (neutralizing antibodies) can be isolated
and subsequently produced in large quantity using recombinant
technology (Corti et al., 2016). Passive infusion of neutralizing
monoclonal Abs (mAbs) has been used for several diseases with
success, including RSV and Ebola virus (Graham and Ambrosino,
2015; Zumla et al., 2016b). Numerous highly potent mAbs against
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SARS-CoV and MERS-CoV have been isolated by multiple
groups all over the world using different methods such as phage
display and direct B cell cloning from immunized animals or
convalescent patients (Sui et al., 2004; Traggiai et al., 2004;
Greenough et al., 2005; van den Brink et al., 2005; Zhu et al.,
2007; Corti et al., 2016). While all of them shows protecting
activity in vitro, several of them have also shown efficacy in
mouse and NHP models (Ter Meulen et al., 2004; Johnson
et al., 2016; Chen et al., 2017; van Doremalen et al., 2017;
de Wit et al., 2018; Xu et al., 2019). The plethora of potent
nAbs have also provided insight into the major antigenic sites
on which vaccine development should focus. A list of mAbs
that show efficacy in vivo against SARS-CoV and MERS-CoV
are summarized in Table 2. Due to the differences in testing
conditions, direct comparison of mAb efficacy should be avoided.
Multiple comprehensive review articles on the subject can also be
found (Prabakaran et al., 2009; Coughlin and Prabhakar, 2012;
Xu et al., 2019).
The binding epitopes of some well-studied mAbs provide
valuable information for the neutralization mechanism and
clinical implications. The majority of the mAbs target the RBD
of the spike protein and prevent viral attachment. For example,
mAb 80R is able to protect both in vitro and a 16 weeks old mouse
model against SARS-CoV Urbani. However, it is unable to protect
other strains due to amino acid variations in the RBD (Zhu
et al., 2007). On the other hand, S230.15 mimics receptor binding
and triggers conformational changes in the SARS S-protein,
completely protecting young and old mice from SARS-CoV
challenge against multiple SARS-CoV, including Urbani, GD03
and SZ16 (Rockx et al., 2008; Walls et al., 2019a). Similar to
SARS-CoV, the majority of mAbs targeting MERS-CoV, such as
MERS-4, MERS-27 (Jiang et al., 2014), m336 (Ying et al., 2014,
2015) and humanized Ab 4C2 and 2E6 (Li et al., 2015) all target
the RBD and prevent the virus from binding to DPP4 with high
potency. Interestingly, the mAb LCA60, isolated from a MERS-
CoV infected patient, binds to RBD region and confers a broader
neutralizing breadth, and is able to neutralize EMC2012 and
London1 strains of MERS-CoV (Corti et al., 2015). Non-RBD
targeting Abs G2 and G4 recognize the non-RBD region of S1
and S2 of MERS-CoV, respectively, showing cross-reactivity with
multiple MERS-CoV variants and can protect hDPP4 transduced
mice from challenge (Wang et al., 2015, 2018). Two nanobodies
isolated from camelids, NbMS10 and HCAb-83, show potency in
hDPP4 transgenic mice by reducing weight loss and increasing
survival after challenge. Interestingly, NbMS10 is able to protect
mice as a therapeutic treatment 3 days post infection (Raj et al.,
2018; Zhao et al., 2018).
While many mAbs show promising properties for clinical use,
two mAbs, REGN3048 and REGN3051, have completed phase
1 clinical trials (NCT03301090). These two mAbs were isolated
from VelocImmune mice (expressing the variable regions of
human Ig heavy and kappa light chain) immunized with MERS
S-protein. Both mAbs show picomolar binding and inhibition of
MERS pseudo particles transduction on Huh7 cells. REGN3048
is able to neutralize seven natural isolates of S variants, and IP
injection of the mAb at 1 day before or after challenge reduces
MERS-CoV RNA levels and lung pathologies in an hDPP4
transgenic mouse model (Pascal et al., 2015). Given the acute
severe phase that is associated with emerging CoV infections, a
major hurdle for therapeutic antibodies and drugs is that early
administration will likely prove most efficacious in clinical care,
as has also been shown with influenza virus, Ebola virus and RSV
immunotherapeutics (Olinger et al., 2012; Qiu et al., 2012; Fry
et al., 2014; Rezaee et al., 2017).
Fusion and Viral Protease Inhibitors
Another critical step for CoV life cycle is membrane fusion and
the subsequent release of the RNA genome for replication (Millet
and Whittaker, 2018). Membrane fusion of CoVs is governed by
the S2 domain of the S-protein (Pallesen et al., 2017; Tortorici and
Veesler, 2019). The S2 stem undergoes a major conformational
change at the two heptad repeat regions (HR1 and HR2) to
bring the host and viral membrane in close proximity for fusion
pore formation (Yuan et al., 2017; Walls et al., 2019b). Multiple
peptidomimetic fusion inhibitors that mimic the HR1 and HR2
of either SARS-CoV or MERS-CoV block the formation of
the helical core and efficiently inhibit membrane fusion in the
micromolar range (Gao et al., 2013; Lu et al., 2014; Xia et al.,
2019). A single report has shown treatment of HR2 peptide 5h
prior to MERS-CoV challenge in an Ad5-hDPP4 transduction
mouse model reduces viral lung titer (Channappanavar et al.,
2015). The ability of these drugs to protect in lethal, high titer
mouse models has yet to be proven.
CoV nsp3 and nsp5 genes encode the papain-like cysteine
protease (PLpro) and 3C-like serine protease (3CLpro),
respectively (Perlman and Netland, 2009). PLpro cleaves the
polyprotein and separates it into nsp1 to 4 while 3CLpro
separates nsp4 to 16 (Ziebuhr et al., 2000; Harcourt et al., 2004).
Since polyprotein processing is a critical step for CoV replication
and transcription, viral proteases are high priority drug targets.
Originally developed as HIV protease inhibitors, LPV and RTV
have low micromolar activity against 3CLpro of both SARS-CoV
and MERS-CoV in vitro (Wu et al., 2004; De Wilde et al., 2014).
Testing in SARS-CoV infected patients has shown beneficial
outcomes, including lowering the viral load, reducing the onset
of ARDS, and lowering mortality rates with LPV and RTV (see
nucleoside analogs) treatments (Chu et al., 2004). However,
most of the drug studies were performed using retrospective
control, sometimes with unbalanced gender ratios, and no
treatment has proven efficacious in a randomized control trial
(Zumla et al., 2016a). In a marmoset model, LPV/RTV treatment
suggested a modest improvement in clinical and pathological
outcome as well as reduction of viral load (Chan et al., 2015).
However, due to different pathological consequences of treated
and untreated group, viral titers were measured at different time
points post-infection and all the experiments were performed
with a relatively small number (n = 3) of single gender (male)
animals (Chan et al., 2015). SARS-CoV and MERS-CoV infection
has been shown to be heavily biased by age and gender, where
elders and males experience more severe complications than
females in clinical cases and mouse models (Karlberg et al., 2004;
Alghamdi et al., 2014; Channappanavar et al., 2017). A single
subject in a case study, an elderly patient, survived a severe
MERS-CoV infection using a combination therapy of LPV/RTV,
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TABLE 2 | Summary of SAR-CoV and MERS-CoV neutralizating antibodies.
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TABLE 2 | Continued
MERS mAbs Epitopes Origins Animal models Treatment timing,
Routes
Dose, route of infection,
Strains
Results References
LCA60 RBD Single B cell cloning
from MERS patients
4 – 6 weeks old
BALB/c transduced
with hDPP4 by Ad5
24 h pre-infection,
prophylactic, IP





Corti et al., 2015
24 h post-infection,
theraputic, IP
Corti et al., 2015




5.2 × 106 PFU,






de Wit et al., 2019
m336 RBD Phage display on navie
human antibody library
hDPP4 transgenic mice 12h pre-infection,
prophylactic, IP








Agrawal et al., 2016





105 TCID50, IN, EMC/2012 Reduce viral RNA
titer and lung
inflammation
Houser et al., 2016
Common marmosets 6 h (IV) and 48 h
(SC) post-infection,
theraputic
5.2 × 106 PFU,









NbMS10 RBD llama immunized with
MERS-CoV RBD








Zhao et al., 2018
1 or 3 days
post-infection,
theraputic, IP
Zhao et al., 2018




hDPP4 transgenic mice 6 h pre-infection,
prophylactic, IP




Raj et al., 2018
IV, intravenous; IN, intranasal; IT, intratracheal; SC, subcutaneous; IP, intraperitoneal.
IFN1α, and ribavirin (Kim et al., 2016). An ongoing clinical trial
in Saudi Arabia has begun to use a combination of LPV/RTV
and IFNβ-1b for laboratory-confirmed MERS-CoV infection
(NCT02845843). Given the importance of 3CLpro I viral life
cycle, it is an attractive target for novel drug development
(Kumar et al., 2017).
Nucleoside Analogs and RdRp Inhibitors
Ribavirin is a guanosine analog that targets RNA dependent
RNA polymerases (RdRp) and has a broad efficacy against RNA
viruses (Loustaud-Ratti et al., 2016). The drug inhibits viral RNA
synthesis and has shown efficacy against HCV and RSV (De
Clercq et al., 2016). Ribavirin inhibits SARS-CoV and MERS-
CoV replication at high concentration in vitro (Tan et al.,
2004; Falzarano et al., 2013a), However, ribavirin enhances viral
replication in the mouse lung and prolongs viral persistence in a
SARS-CoV mouse model (Barnard et al., 2006a). Although not
effective as a monotherapy, ribavirin shows a synergistic effect
against SARS-CoV and MERS-CoV when combine with IFN
(Momattin et al., 2013). In a rhesus macaque model, MERS-CoV
infected monkeys show improvement after treating with ribavirin
and IFN-α2b (Falzarano et al., 2013b). Furthermore, ribavirin
has been used in clinical settings during SARS-CoV and MERS-
CoV outbreaks (Omrani et al., 2014; Khalid et al., 2015; Shalhoub
et al., 2015). While some studies report positive outcome after
treatment with ribavirin + IFN, others suggest no significant
improvement (Dicaro et al., 2004; Khalid et al., 2015). Due to the
variation in dosage and time of administration and the lack of
control, the efficacy of using ribavirin in patients is inconclusive.
Mechanistically, studies show that recombinant CoV with a
deleted proof-reading exonucleases N (ExoN) shows higher
sensitivity toward ribavirin. These results indirectly suggest that
the low activity of ribavirin in CoV could be explained by the
presence of a proofreading exonucleases N (ExoN, nsp14) which
can excise the drug from the viral mRNA in CoVs (Smith et al.,
2013; Ferron et al., 2017).
Two nucleoside analogs, β-D-N4-Hydroxycytidine (NHC)
and GS-5734 (remdesivir), have shown high efficacy against CoVs
and are less sensitive to ExoN (Sheahan et al., 2017, 2020; Agostini
et al., 2018, 2019). NHC is a cytidine analog and has recently
been shown to inhibit multiple viruses, including influenza virus,
RSV and Ebola virus (Reynard et al., 2015; Urakova et al., 2017;
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Yoon et al., 2018). It has micro-molar EC50 against both alpha
and beta CoVs including SARS-CoV and MERS-CoV (Barnard
et al., 2004; Pyrc et al., 2006; Agostini et al., 2019). Currently
under clinical development for Ebola viruses, remdesivir is a
nucleoside prodrug that is effective against multiple other RNA
viruses including Nipah viruses, RSV, and CoVs (Lo et al., 2017;
Sheahan et al., 2017). Remdesivir has sub-micromolar inhibition
concentrations in a broad range of CoVs including SARS-CoV,
MERS-CoV, and hCoV-NL63, as well as pre-pandemic bat-CoVs
WIV1 and SHC014 in an in vitro human airway epithelial (HAE)
model (Sheahan et al., 2017; Agostini et al., 2018). Prophylactic
administration (one day pre-infection) of remdesivir can mitigate
disease by reducing the viral titer and lung pathology in
lethal mouse models challenged with a mouse adapted SARS-
CoV MA15. Remdesivir also shows therapeutic activity when
administered early at one day post-infection (corresponding to
7–10 days after the onset of symptoms in human infection).
However, treatment initiated two days post infection does not
improve disease outcomes, although the murine disease model
is more compressed than in humans (Sheahan et al., 2017).
Importantly, remdesivir shows excellent prophylactic protection.
Rhesus macaques are completely protected from MERS-CoV
infection as scored by lung pathology and clinical score as well as
inhibited viral growth. Therapeutic treatment 12-h post infection
shows moderate improvement of clinical outcomes on NHPs
(de Wit et al., 2020). The parental nucleoside of remdesivir,
GS-441524, has also shown to be effective for treating FIP, a
disease caused by the α-CoV FIPV (Murphy et al., 2018; Pedersen
et al., 2019). Currently, NHC and remdesivir are the only broadly
effective antiviral drugs against all SARS-like, MERS-like, human
contemporary, and animal CoVs (Sheahan et al., 2017; Agostini
et al., 2018; Murphy et al., 2018; Pedersen et al., 2019). Some
antiviral drugs, such as chloroquine and T-705, also show efficacy
in vitro and are under consideration for the current COVID-19
outbreak (Wang et al., 2020).
HOST FACTOR INHIBITORS AND
IMMUNO-MODULATORS
Host Protease Inhibitors
Like all class I viral fusion proteins, CoV S glycoproteins require
proteolytic cleavage by host proteases for membrane fusion
and viral entry (Belouzard et al., 2012; White and Whittaker,
2016; Millet and Whittaker, 2018). Two cleavage events have
been characterized in SARS-CoV and MERS-CoV. The first
cleavage event separates the head (S1) and the fusion stem (S2)
by cutting the S1/S2 junction (Millet and Whittaker, 2015).
The second cleavage event occurs at the S2’ site which is
usually located immediately upstream of the fusion peptide
(Belouzard et al., 2009). Multiple proteases have been shown
to be involved in the cleavage events, including cathepsin-L,
trypsin-like serine proteases, transmembrane serine proteases
(TTSP) and proprotein convertases such as furin (Millet
and Whittaker, 2015). Cathepsin-L inhibitors MDL28170 and
SSAA09E1 block SARS-CoV pseudotyped particle infection in
pre-treated 293T cells (Simmons et al., 2005; Adedeji et al., 2013).
While a peptidomimetic furin substrate, decanoyl-RVKR-
chloromethylketone, has been shown to inhibit cleavage of MERS
S-protein and block infection in multiple cell lines including
normal human bronchial epithelial cells (NHBE), the in vivo
potency of this approach is less certain (Gierer et al., 2014; Millet
and Whittaker, 2014; Matsuyama et al., 2018).
Host Receptor Inhibitors
The blocking of receptor interactions is also a target of antiviral
development. N-(2-aminoethyl)-1 aziridine-ethanamine
(NAAE) blocks the interaction of SARS S-protein and ACE2
and inhibits S-mediated cell-to-cell fusion at millimolar
concentrations (Huentelman et al., 2004). Similarly, an Ab
blocking DPP4 can also inhibit MERS-CoV infection on primary
bronchial epithelial cells (Raj et al., 2013). Importantly, the
S-proteins of SARS-CoVs and MERS-CoV interact with their
receptors outside of the active sites. Therefore, it would be of
interest to develop inhibitors that do not affect the normal
function of the host proteins but abolish the interaction of the
CoV and receptor. Otherwise, long term inhibition of cellular
proteins could have adverse effects on the host. For instance,
inhibition of ACE2 may cause hypertension (Danilczyk and
Penninger, 2006). Additionally, DPP4 is also responsible for
multiple cellular functions including immune homeostasis, stem
cell development, metabolism and T-cell regulation, and hence
is not an ideal target for MERS-CoV infection (Matteucci and
Giampietro, 2016; Ou et al., 2019).
Other Host Factor Inhibitors
Another attractive target to inhibit CoV infection is the host
metabolic pathways essential for CoV life cycles. CoVs replicate
and transcribe in membrane-bound vesicles derived from the
host’s rough ER (Snijder et al., 2006; Stertz et al., 2007;
Reggiori et al., 2010). MERS-CoV infection upregulates the
biosynthetic pathways of multiple major lipogenic enzymes,
including fatty acid synthase (FAS), acetyl-CoA carboxylase
(ACC) and HMG-CoA synthase (HMGCS) (Yuan et al., 2019).
AM580, which targets the major lipid biosynthesis transactivator
n-SREBPs by interfering with and downregulating global lipid
synthesis (Goldstein et al., 2006; Yuan et al., 2019), inhibits
the replication of multiple viruses including influenza virus,
Zika virus, Enterovirus-A71 and MERS-CoV (Yuan et al., 2019).
Remarkably, MERS-CoV viral titer is reduced by 1,000- to
1,000,000-fold in the presence of AM580 in Huh7 cells or a
human intestinal organoid model, respectively, and IP injection
of AM580 for 3 days protects a human hDPP4 transgenic mouse
model from MERS-CoV lethal challenge (Yuan et al., 2019).
Immune Modulators
Corticosteroids
SARS-CoV and MERS-CoV both cause lung inflammation and
can progress into severe respiratory syndrome. Lacking direct
antiviral effect, corticosteroids are an immune suppressor which
is administrated to severe patients to alleviate lung inflammation.
However, immune suppression could also facilitate viral
replication. Therefore, corticosteroids are often administrated
with antiviral or other immune modulators, such as IFN which
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can activate the immune system. Retrospective and prospective
clinical studies have shown mixed observation in treating
SARS-CoV and MERS-CoV patients with corticosteroids, IFN
and ribavirin; while some showed a positive effect, others
showed no difference.
IFNs
SARS-CoV and MERS-CoV are able to suppress the induction
of IFN synthesis by multiple mechanisms including inhibition
of the IFN signal transduction pathways and evading detection
by pattern recognition receptors (PRRs) and toll-like receptors
(TLRs) (Frieman et al., 2008; Lim et al., 2016; Mubarak et al.,
2019). Therefore, external administration of IFN regiments could
re-initiate the antiviral immune response in the host. During the
SARS-CoV and MERS-CoV outbreaks, IFN-α, IFN-β, and IFN-γ
were used in combination with various antiviral drugs, including
LPV/RTV, ribavirin, corticosteroids and poly I:C (Zumla et al.,
2016a). Although most of the clinical reports are positive, there is
no consensus on the efficacy of IFN treatment in CoV infection.
In animal model studies, IFN treatment is only effective when
administrated at early time point for both SARS-CoV and MERS-
CoV (Channappanavar et al., 2016, 2019). Furthermore, many
of the clinical studies were confounded by multiple factors,
including IFN dosages, combination of different antivirals, and
the stage of infection (Mo and Fisher, 2016). For instance, some
studies targeted patients in the late stage of infection and show
a worse survival rate than average (Al-Tawfiq et al., 2014; Khalid
et al., 2014). Based on multiple research reports, IFN-β shows the
best efficacy in treating MERS-CoV infection (Chan et al., 2013;
Hart et al., 2014; Kim et al., 2016). Currently, an open labeled, well
controlled clinical study is aiming to test a set dose of LPV/RTV
and IFN-β in treating MERS-CoV. The trial will probably provide
insight into treating MERS-CoV infection in human population.
THE CURRENT SARS-CoV-2
OUTBREAK: A CHALLENGE, AN
OPPORTUNITY
In December 2019, a new CoV outbreak started in Wuhan,
China, a megacity with a population of 11 million. With an
estimated basic reproduction number (R0) of 1.4 – 2.5, SARS-
CoV-2 quickly spread to every province in China and began to
spread globally by the end of January 2020 (Zhou et al., 2020),
and was declared a worldwide pandemic in March 2020 by the
World Health Organization. SARS-CoV-2 is capable of human-
to-human transmission via either symptomatic or asymptomatic
patients (Rothe et al., 2020). The high mutation rate of CoVs
and the possibility of super-spreader could potentiate the
continuous spreading globally. Originally from bat, the SARS-
CoV-2 Is 96% identical to a bat CoV designated RaTG13, isolated
from a cave in Yunnan Province, China and belongs to the
betacoronavirus 2b family, as does SARS-CoV (Zhou et al.,
2020). However, the S-proteins between SARS-CoV and 2019
nCoV share only 76–78% sequence similarity, rendering the
current experimental vaccines and antivirals unlikely to be fully
protective against SARS-CoV-2. As many group 2b SARS-like
CoV have pre-epidemic potential, vaccines and countermeasures
should be targeted against all of these strains to maximally
protect against current and future threats to the global health and
economy (Menachery et al., 2015, 2016).
After two CoV outbreaks in the last two decades, the
public health officials and clinicians have experience in
preventing spread and treating SARS-CoV-2 patients. Prompt
communication between governments, quick quarantine
procedures, and rapid viral detection assays have helped
minimize SARS-CoV-2 cases in other countries thus far.
Additionally, the scientific community has developed novel
vaccine strategies and experimental antivirals to fight emerging
CoV. New vaccines that specifically targeting SARS-CoV-2 are
under development. Moderna had started a phase 1 clinical trial
on an RNA vaccine (mRNA-1273) that encodes the prefusion
stabilized form of SARS-CoV-2 S-protein (NCT04283461).
Although there are no published studies of a RNA vaccine
platform against CoV, the RNA platform has shown efficacy
against multiple other viral infectious diseases including
influenza, rabies, Flavivirus, and Ebola viruses in experimental
animal models (Zhang et al., 2019). Furthermore, pre-clinical
data of the Zika virus mRNA vaccine (mRNA-1893) from
Moderna has shown protection against Zika virus and abrogated
maternal transmission of Zika virus in pregnant mice (Richner
et al., 2017; Jagger et al., 2019). Broad-spectrum antivirals which
have shown efficacy against multiple CoVs have the potential
to treat SARS-CoV-2 (Sheahan et al., 2017, 2020). Given the
high number of infected patients and at risk individuals, the
current situation provides an opportunity to initiate clinical
trials for (a) vaccine formulation designed to protect uninfected
people, (b) broad spectrum antivirals to treat infected individuals
and (c) formulation of immune modulators to alleviate clinical
pathologies. A well-designed clinical trial could not only
ameliorate the current situation, but also lay the foundation
for future CoV outbreaks. Supported by a recent study on
SARS-CoV-2 (Wang et al., 2020) and multiple research studies
on SARS and MERS-CoVs (Sheahan et al., 2017, 2020; de Wit
et al., 2020) and a single clinical report (Holshue et al., 2020),
remdesivir hold promises as treatment for SARS-CoV-2. The
Chinese government has started a clinical trial using remdesivir
for treating SARS-CoV-2 patients with mild to severe symptoms
(NCT04252664, NCT04257656). On the clinical side, if time
and resources permit, a centralized repository that records
and digitizes infection cases would aid future medical and
epidemiology studies through machine learning programs.
Finally, the current situation also provides an opportunity to
develop unconventional treatments, such as gene therapy, to
target infectious diseases.
UNCONVENTIONAL VACCINES AND
THERAPEUTICS – GENE THERAPIES
The field of gene therapy has undergone rapid growth in the last
10 years. Although mainly focused on rare genetic diseases, its
potential in treating infectious diseases should not be discounted.
One of the leading vectors, adeno-associated virus (AAV), has
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proven to be safe for human use and multiple AAV-based gene
therapy drugs are approved by the FDA and the EMA (Kay et al.,
2000; Kaplitt et al., 2007). So far, the only report of use of AAV in
CoV is as a DNA vaccine to deliver SARS-CoV spike protein for
immunization (Du et al., 2008). Given the recent developments
in human antibody cloning technologies, AAV holds a promising
potential to be a hybrid of vaccine and therapeutic which acts
as a passive immunization vector to provide protection for the
outbreak and as a therapeutic in early time scales.
AAV as a Vector for Passive
Immunization Against Emerging CoV
The Vectors – Safety
AAV is a non-pathogenic, non-enveloped, 4.7 kb single-stranded
DNA virus belonging to the Dependoparvovirus genus within
the family Parvoviridae (Cotmore et al., 2014). AAV infects
a wide variety of animals, from bearded dragons to humans.
Natural AAV isolates have different tissue tropisms in humans
and can be reverse engineered to better fulfill various medical
needs. To target SARS-CoV, MERS-CoV and other respiratory
virus infections, a human airway tropic AAV is needed. Multiple
reports have demonstrated that natural isolates AAV5 (Zabner
et al., 2000), AAV6 (Limberis et al., 2009), and AAV9 (Adam et al.,
2014) as well as engineered vectors AAV2.5 (Li et al., 2009) and
AAV2.5T (Excoffon et al., 2009) are able to transduce human lung
epithelial cells, including primary human airway epithelial (HAE)
cultures. Although there is a high prevalence of nAbs against
AAVs in the human population, new technologies have been
developed to engineer AAV to evade humoral immune responses
(Tse et al., 2015, 2017). These developments potentially allow for
the delivery of CoV vaccines or immunotherapeutic directly to
the mucosal compartments of the lung.
The Package – Flexibility
Passive immunization of AAV can be developed as a platform
technology in which the nAb can be quickly exchanged to
target specific pathogens. Multiple studies have shown passive
immunization using AAV is effective against viral infectious
diseases such as HIV, (Balazs et al., 2012; Lin and Balazs,
2018) Ebola, (Limberis et al., 2016) influenza, (Balazs et al.,
2013; Laursen et al., 2018), and others (Nieto and Salvetti,
2014). The package for delivery is extremely flexible, from
authentic immunoglobulins (IgG) to immunoadhesins (IA) to
single chain variable fragments (scFv) to bi-specific antibodies
(Naso et al., 2017). Furthermore, a combination of Abs, small
antiviral peptides and immuno-modulators can be co-delivered
at the same time to achieve multidimensional therapy. Although
AAV-based passive immunization has not yet been tested as
therapeutic, it could serve as a fast-acting prophylactic alternative
to traditional vaccines.
The Timing – Quick
The most important aspect to control an outbreak is to reduce
the spread by protecting the population from infection. However,
there is a lag time between the beginning of an outbreak
and the development of an effective vaccine in which the
population is completely vulnerable. Prophylactic treatments,
such as infusion of Abs and antivirals, could protect individual
for a short duration. However, these prophylactic treatments
require constant intake to stay effective and are toxic as well as
financially impractical for long-term use (Hansel et al., 2010).
AAV-based passive immunization could perfectly fill the vacuum
by protecting the population before the arrival of a vaccine. Since
AAV is a platform technology, anti-viral packages can be swapped
and tested quickly, within a month (Strobel et al., 2019). After
administration in animals, protection can be achieved in less than
a week, faster than any vaccine strategies. In an influenza study,
AAV9 delivery of IA via intranasal inoculation protected animals
from lethal influenza challenges including H5N1, H1N1 and
H1N1 1918 within 3 days of AAV administration (Limberis et al.,
2013). Unlike traditional gene therapy in which the transgene
lasts for long periods of time, the natural turnover rate of airway
epithelia means that the nAb introduction is not permanent,
reducing the chance that the host will produce antibodies
targeting the therapeutic antibody delivered by AAV (anti-drug
antibody responses) (Nieto and Salvetti, 2014). Therefore, AAV-
based passive immunization is a quick and excellent option to
deploy in an outbreak situation for emerging infectious diseases.
The Challenges
AAV-based gene therapy has great potential for treating viral
infectious diseases. However, there are multiple hurdles for
AAV-based gene therapy to achieve its full potential. (1) Low
transduction efficiency, (2) pre-existing nAb against AAVs, (3)
transgene toxicity and loss of expression, and (4) extremely high
price tag (Colella et al., 2018; Kaemmerer, 2018). Fortunately,
multiple strategies have been developed to address these hurdles
(Tse et al., 2015). For instance, through vector engineering, a
new generation of AAV vectors can evade pre-existing nAbs
while retaining a good transduction profile in the respiratory
system (Li et al., 2009; Tse et al., 2017). For rare genetic diseases,
life-long gene expression is important for therapeutic purposes
but could cause toxicity. On the contrary, for emerging CoVs,
the goal is a short-term protection from the virus. Therefore,
AAV can target epithelial cells that have a regular turn-over rate,
hence providing short-term protection and preventing transgene
toxicity. AAV-based therapies are known for their extremely
high prices, sometime up to a million US dollar per treatment.
However, the prices are inflated due to the small market size of
rare genetic diseases and the cost for drug development. Given
the huge market size of infectious diseases, the price for AAV-
based therapy for infectious diseases should be more reasonable.
Unlike rare genetic diseases and other infectious diseases, an
emerging CoV outbreak is uniquely suitable for AAV-based
passive immunization as a short-term protection therapy before
vaccine deployment.
CONCLUSION
The continuous development of vaccines, antivirals, and
hopefully gene therapies will provide an arsenal for combating
and controlling emerging CoV diseases. For vaccine
development, understanding the antigenicity and neutralizing
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antibody footprints of different CoVs could aid the development
of broad-spectrum vaccines and, ultimately, the possibility of a
universal CoV vaccine. Vaccine formulation, including dosage
and adjuvants, should be tested systemically and, if possible,
on animal models that reflects the genetic variation of the
human population. A deeper understanding of the basic biology
of CoV and host-virus interaction can lead to the discovery
of druggable targets. Importantly, we should not overlook the
potential of the existing broad-spectrum antivirals and should
start clinical trials on these drugs in a timely fashion. Prevention
is always the best treatment, and constant viral surveillance of
wild animals for potential emerging CoVs is extremely important.
Testing the outbreak potential of heterologous SARS- and MERS-
like viruses with different spike proteins could better prepare
society from the next outbreak. A centralized digital database
that collect public health and clinical information of the current
outbreak would allow global retrospective studies in the future
using machine learning and other big data analysis. On the
research side, quick, reliable and easily employed viral testing
kits should be developed. Innovative technologies such as gene
therapy should be adequately explored for their potential to
combat CoVs and act as another line of defense against elusive
emerging viral diseases. The current SARS-CoV-2 poses a huge
challenge for society; however, given experience with emerging
CoVs and global effort, it is hoped that the impact of the outbreak
will be minimal.
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